NEW YORK (GenomeWeb News) – CombiMatrix yesterday registered with the US Securities and Exchange Commission to sell up to 2,305,274 shares upon the exercise of outstanding warrants.
 
The company said in its SEC filing that if all of the warrants are exercised, it will net up to $19,510,926 before deducting around $17,500 in expenses.
 
CombiMatrix said it intends to use the proceeds for working capital, research and development, general and administrative expenses, and sales and marketing activities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.